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KEY POINTS
 Left ventricular outflow tract (LVOT) obstruction is a complex interplay of anatomic, dynamic,
and mechanical factors and may occur after surgical or transcatheter intervention.
 Adequate imaging evaluation with computed tomography and echocardiography is essential
before transcatheter mitral intervention to assess the risk of LVOT obstruction.
 There are several experimental therapeutic options for LVOT obstruction post–transcatheter
mitral valve replacement, but to date outcomes remain suboptimal; prediction and
preemptive therapy may be a more promising option.

INTRODUCTION
Transcatheter mitral valve replacement (TMVR)
is emerging as a promising therapeutic option
for patients with mitral valve disease, in particular for those at high surgical risk. Clinical data
accumulated thus far have demonstrated the
complexity and challenges of this new intervention. A recognized potential complication
of TMVR is obstruction of the left ventricular
outflow tract (LVOT) by the new valve prosthesis. In the current review, the authors summarize the known mechanisms of LVOT
obstruction following mitral valve intervention,
describe pre-TMVR imaging for prediction
of iatrogenic LVOT obstruction, and discuss
potential therapeutic options if it should
occur.

LEFT VENTRICULAR OUTFLOW TRACT
OBSTRUCTION FOLLOWING MITRAL
VALVE SURGERY
Surgical Mitral Valve Repair
LVOT obstruction following mitral valve intervention was first described by Termini and colleagues1 in 1977 following surgical mitral valve
repair. They reported systolic anterior motion
(SAM) of the mitral valve apparatus accompanied by a paradoxic motion of the interventricular septum, resulting in narrowing of the
aortomitral angle and dynamic LVOT obstruction.1 Kreindel and colleagues2 later described
the development of SAM after semirigid ring
insertion, caused by the Venturi effect, in which
the pressure drop with systolic emptying pulls
a redundant anterior mitral leaflet (AML) toward
the LVOT (see Fig. 2). Milhaneau and
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colleagues3 described an LVOT obstruction
prevalence of 4% to 5% following mitral valve
repair that reached 14% in patients with “highrisk” anatomic factors: mitral valve insufficiency
of degenerative origin with excess leaflet tissue,
a nondilated left ventricular cavity, and a narrow
aortomitral angle. Later, echocardiographic
studies in patients undergoing mitral valve repair
demonstrated an anterior displacement of the
coaptation point toward the LVOT caused by
redundant mitral leaflets.4 As a result, leaflet
coaptation of the AML and posterior mitral leaflets (PML) occurs more at the base of the AML
with more leaflet slack close to the LVOT with
potential for obstruction. In fact, the “sliding
leaflet” surgical technique developed by Carpentier consisted of reduction of the height of
the PML and efficiently lowered the occurrence
of LVOT obstruction following mitral valve
repair.5
In a small study in patients with myxomatous
mitral valve disease undergoing surgical repair,
SAM/LVOT obstruction was found to be associated with a relatively lower AML/PML length ratio,
as assessed preoperatively by transesophageal
echocardiography.6 Based on their findings, the investigators suggested a greater reduction in the
posterior leaflet height during surgery, if the above
ratio is 1.3 or lower, particularly if the distance from
the coaptation point to the septum is 2.5 cm or
less.6 In a more recent echocardiography study
by Varghese and colleagues,7 independent predictors of developing SAM after surgical mitral
valve repair were a small left ventricle (end diastolic
diameter <45 mm), tall posterior leaflet height
(>15 mm), a narrow angle between the planes of
the aortic and mitral annulus (<120 ), a short
coaptation-septum distance (<25 mm), and an
enlarged basal septal diameter (15 mm). The investigators suggested that the above parameters
might guide the operators to consider appropriate
measures to minimize the risk of LVOT obstruction,
such as an upsized ring, ensuring a postrepair posterior leaflet height less than 15 mm and avoiding
inotropes on weaning from bypass.7

Surgical Mitral Valve Replacement
LVOT obstruction has also been described
following surgical mitral valve replacement.8–10
Anatomically, the aortic and mitral valves are in
fibrous continuity (Fig. 1); therefore, placement
of a prosthetic valve in the mitral annulus might
result in projection of the prosthesis into the left
ventricular cavity in close proximity to the aortic
annulus.8,10 In addition, preoperative redundancy of the chordal apparatus, such as mitral
regurgitation secondary to mitral valve prolapse,
coupled with decreased chordal support
following surgery, can contribute to SAM of
the AML remnants after mitral valve replacement with preservation of the valve leaflets.11
Of note, the decrease in left ventricular volume
overload following resolution of mitral regurgitation may itself cause a reduction in LVOT area.
This further reduction in the circumference of
the LVOT induced by the traction of the prosthesis tightly sutured to the MV annulus, particularly with small devices (30 and smaller), may
further increase the potential of LVOT
obstruction.12

TRANSCATHETER MITRAL VALVE
REPLACEMENT AND LEFT VENTRICULAR
OUTFLOW TRACT OBSTRUCTION
Pathophysiology of Left Ventricular Outflow
Tract Obstruction after Transcatheter Mitral
Valve Replacement
LVOT obstruction is a known complication of
TMVR. TMVR in mitral annulus calcification
(MAC) has the highest associated rate of
LVOTO, followed by TMVR in degenerative
ring (valve-in-ring [ViR]), then TMVR valve-invalve (ViV). The mechanisms of obstruction are
similar to those previously discussed with surgical mitral repair and replacement, although
with certain distinctions (Table 1).13 Insertion of
transcatheter heart valve (THV) into the mitral
valve apparatus compresses the existing LVOT
area, whereas the “native” portion of the
LVOT, confined to the basal septum and intervalvular fibrosa, remains mostly unchanged.14,15

Fig. 1. Mitral valve with corresponding computed tomographic
reconstructed image.
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Table 1
Factors contributing to LVOT obstruction following transcatheter mitral valve replacement
Anatomic Factors

Dynamic Factors

Mechanical Factors

1. Small predicted neo-LVOT
(<5189.4 mm2)
2. Redundancy of the anterior
mitral leaflet
3. Small LV cavity
4. Hypertrophic cardiomyopathy
5. Septal hypertrophy or
asymmetric septal hypertrophy
6. Chordal redundancy
7. Mitral annular calcification
8. Aortomitral angle

1.
2.
3.
4.
5.

1. Flaring of transcatheter
devices placed in the
mitral position
2. Extreme ventricular
deployment of
transcatheter
heart valve
3. Interaction with
aortic prosthesis

Hypercontractile LV
Atrial fibrillation
Volume status/loading conditions
Hypertrophic cardiomyopathy
Left ventricular remodeling

Abbreviation: LV, left ventricular.

This compressed and remodeled “neo-LVOT” is
delineated anteriorly by the patient’s native
AML in ViR and valve-in-MAC TMVR. In TMVR
ViV, the most anterior frame of the bioprosthetic
device impinges on the neo-LVOT. Implantation
of the transcatheter heart valve in a bioprosthesis results in opening of the leaflets of
the surgical bioprosthesis, which are then pinned
open by the stent of the transcatheter heart
valve toward the LVOT, potentially resulting in
a fixed systolic LVOT obstruction, resulting in a
phenomenon known as “permanent anterior
motion” of the bioprosthetic leaflet.16–18
Mechanical factors at the time of TMVR
deployment also contribute to the added risk
of LVOTO during the procedure. In an effort to
minimize the risk of device embolization, structural operators inherently oversize transcatheter
heart valves for the mitral position and flare the
transcatheter heart valve to promote valve
anchoring.14,15,19 In ViV TMVR, an understanding
of the bioprosthetic leaflet architecture also
helps in prediction modeling for LVOTO. Bench
studies have shown that bovine pericardial leaflets do not crinkle during ViV procedures. In
contrast, porcine leaflets stand tall and may
result in more significant LVOT obstruction.20
Key to successful TMVR is an understanding of
the risk factors for LVOTO known for decades
by mitral surgeons after surgical mitral valve replacements, as well as left ventricular cavity
size, septal hypertrophy,21 and aortomitral angle
that are more dangerous in the transcatheter
world, where device placement cannot be
manipulated postimplantation.

Incidence of Left Ventricular Outflow Tract
Obstruction
In a multicenter retrospective study evaluating
TMVR outcomes in patients with severe MAC

(n 5 64), Guerrero and colleagues19 reported a
hemodynamically significant LVOT obstruction
in 6 patients (9.3%) after valve deployment.
The average peak LVOT gradient in these patients was 72 mm Hg (range, 39–100 mm Hg).
In a more recently published study of 194 patients undergoing TMVR (107 ViV patients, 50
ViR patients, and 37 valve-in-MAC patients) the
investigators encountered LVOT obstruction in
26 (13.4%), with a significantly higher rate in
the valve-in-MAC group compared with the ViR
and ViV groups (54.1% vs 8.0% vs 1.9%;
P<.001).22 Of note, no differences in the occurrence of LVOT obstruction were found between
the different types of transcatheter heart valves,
sizes of transcatheter heart valves, or access site
used. In the evolving era of TMVR, larger scale
study of consecutive patients will be needed to
define the actual prevalence of LVOT obstruction following implantation of different transcatheter heart valves.

Outcomes of Left Ventricular Outflow Tract
Obstruction Following Transcatheter Mitral
Valve Replacement
Limited data have been accumulated to date
regarding the clinical outcomes of LVOT
obstruction following TMVR. Guerrero and colleagues19 reported the outcomes of 64 patients
from 32 centers who underwent TMVR with
compassionate use of balloon-expandable
valves.
The
mean
patient
age
was
73  13 years, 66% were women, and the
mean Society of Thoracic Surgeons predicted
operative mortality score was 14.4  9.5%. Access was transatrial in 15.6%, transapical in
43.8%, and transseptal in 40.6%. Thirty-day allcause mortality was 29.7%; 84% of the survivors
with follow-up data available were in NYHA
functional class I–II at 30 days (n 5 25). Among
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the 6 patients (9.3%) who had LVOT obstruction
with hemodynamically significant compromise,
mortality was high (83%): 1 patient died during
the procedure; 1 was stabilized medically but
died of pneumonia 9 days later; 1 was converted
to open surgery for valve retrieval and died
hours later; 1 was treated with simultaneous kissing aortic and mitral balloon valvuloplasty with
significant improvement in LVOT gradient but
died 48 hours later due to multiorgan failure; 1
was treated with emergent percutaneous
alcohol septal ablation with resolution of the
gradient and hemodynamic recovery but died
4 days later of complete heart block secondary
to the ablation; and 1 patient was treated successfully with emergent alcohol septal ablation
and was discharged home. Recently, Yoon and
colleagues described the outcomes of TMVR in
194 patients of whom 26 patients (13.4%) developed LVOT obstruction. In their study, patients
with LVOT obstruction had significantly higher
procedural mortality compared with those
without LVOT obstruction (34.6% vs 2.4%;
P<.001).

IMAGING FOR TRANSCATHETER MITRAL
VALVE REPLACEMENT—PREDICTING LEFT
VENTRICULAR OUTFLOW TRACT
OBSTRUCTION AND PERIPROCEDURAL
IMAGING
Imaging assessment of the mitral valve anatomy
is crucial before TMVR procedures and the essentials of imaging include computed tomography
(CT) and transesophageal echo, summarized in
Table 2.

Computed Tomography
CT is the main imaging modality for pre-TMVR
device sizing and assessment of potential procedural obstacles. The mitral annulus has a
nonplanar, saddle-shaped configuration with
the posterior peak formed by the insertion of
the PML and the anterior/aortic peak being
continuous with the aortic annulus. This complex
nonplanar 3-dimensional (3D) circumference can
be delineated on CT by segmental tracing of the
mitral annulus during stepwise rotation around
the left ventricular long axis.23 Noticeably, the
anterior projection of the saddle-shaped annulus
protrudes into the LVOT trajectory. Implantation
of a transcatheter heart valve in the anterior projection axis would be thus likely to cause LVOT
obstruction.23 Accordingly, it has thus been proposed that the mitral annulus should rather be
addressed in pre-TMVR imaging as a D-shaped
structure, and24 this can be achieved by linear

Table 2
Imaging essentials for TMVR and evaluation
of LVOT obstruction
Echocardiography
Transthoracic echo
(TTE)
 Evaluation of LV
size and function
 Assessment of wall
thickness and
septal hypertrophy
and baseline LVOT
gradient
 Evaluation of
anterior and
posterior mitral
leaflets and
redundancy
 Presence of
preexisting SAM
or chordal SAM

Computed
Tomography
 Assessment of
aortomitral angle
 Evaluation of mitral
annular calcification
 Measurement of
neo-LVOT
 Device selection
using specific
models to predict
neo-LVOT
measurements
 May be useful for
generation of 3D
printed models for
procedure planning

Transesophageal
Echo (TEE)
 Assessment of
dynamic LVOT
obstruction during
TMVR procedure
 Confirm valve
positioning and
function

tracing of the distance between by medial and
lateral fibrous trigones, excluding the anterior
aortomitral continuity.24 The “neo-LVOT” and
its trajectory can be then evaluated readily using
virtual simulation of transcatheter heart valve implantation. Eventually, the newly formed annular
D shape has a smaller circumference and is
considerably more planar than the native saddle
shape. This allows the design of an S curve of
orthogonal fluoroscopic views that may assist
device implantation.25
Wang and colleagues18 demonstrated the validity of preprocedural computer-aided virtual
simulation models for prediction of LVOT
obstruction following TMVR in 38 patients with
degenerative surgical mitral ring, bioprosthesis,
or severe native MAC. The neo-LVOT area was
efficiently predicted (R2 5 0.8169, P<.0001) by
pre-TMVR LVOT modeling, on validation with
post-TMVR CT measurements.18 In their study, a
predicted neo-LVOT surface area of less than or
equal to 189.4 mm2 was found to have 100%
sensitivity and 96.8% specificity for prediction of
TMVR-associated LVOT obstruction.18 Integration of computer-assisted design and generation
of 3D printing of heart models has been also
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suggested for accurate ex vivo bench testing of
mitral transcatheter heart valves in patientspecific anatomy.15,26 Three-dimensional models
can be physically generated with putative transcatheter heart valves deployed in different left
ventricular landing zones/depth of implantation
within the patient’s mitral annulus, ring, or bioprosthesis. The post-TMVR neo-LVOT area can
be then assessed for the proposed transcatheter
heart valve by various depths of left ventricular
deployment and angulations of the transcatheter
heart valve delivery system.26 Ultimately,
computer-assisted tomography and printing
allow personalized estimation of patient-specific
3D anatomy, overcoming the main limitation of
traditional 2D imaging planes.

Transesophageal Echocardiography
The compound structure and function of the
native mitral valve mandates a thorough preprocedural imaging assessment.27 Transesophageal
echocardiography (TEE) is well established in
assessment of dynamic LVOT obstruction in hypertrophic cardiomyopathy and in predicting
SAM following mitral valve surgery.28 Recent pilot studies have shown that 3D-TEE might be
effective in the prediction of LVOT obstruction
in patients undergoing transcatheter ViV intervention, by assessment of the spatial relationship between the existing mitral bioprosthetic
struts and the intraventricular septum29 as well
as the intraprocedural changes in the aortomitral
angle.30
LVOT obstruction can be evaluated and diagnosed by TEE during the TMVR procedure. TEE
may demonstrate a narrowed LVOT with
displacement of the AML toward the LVOT
that can be either fixed or dynamic. In the
setting of ViV, the stent struts of the transcatheter heart valve are often detectable on TEE
within the LVOT.30 Doppler echocardiography
is also useful to detect an elevated peak
gradient across the LVOT. Invasive hemodynamic monitoring during the TMVR procedure
is essential to recognize the hemodynamic effects of LVOT obstruction, assess the level of
obstruction within the outflow tract, and monitor
the response to treatment.

THERAPEUTIC OPTIONS FOR LEFT
VENTRICULAR OUTFLOW TRACT
OBSTRUCTION POST-TRANSCATHETER
MITRAL VALVE REPLACEMENT
The first-line therapy for LVOT obstruction in hemodynamically stable patients is medical management (Table 3). In many cases, small

Table 3
Therapeutic options for LVOT obstruction
following TMVR procedures
Medical
Management

 Volume loading
 Vasopressors
 Beta-blockers in the
setting of tachyarrhythmias

Alcohol Septal
Ablation

 May be considered
in the setting of acute
obstruction although
limited evidence
 Some advocate
performing procedure
before TMVR in high-risk
cases; however there is
limited evidence

LAMPOON
 Laceration of the anterior
(Laceration of
mitral leaflet performed
the AML to
before TMVR to limit
Prevent LVOT
obstruction caused
ObstructioN)
by SAM
 Being studied in a
clinical trial; limited
evidence to date
Perfusion
Balloon
Inflation
in LVOT

 Perfusion balloon
inflated in the LVOT
to maintain patency
during TMVR deployment
preventing protrusion of
TMVR into LVOT
 Case report only;
limited evidence

ventricular dimensions and hypercontractility
contribute to LVOT obstruction and therefore
ensuring adequate volume status with intravenous volume loading is of key importance. Inotropes should be used carefully with the
understanding that inotropes and vasodilators
may exacerbate dynamic obstruction, as in the
case of hypertrophic obstructive cardiomyopathy. The use of beta-blockers should be considered in the setting of tachycardia as well as
vasoconstricting agents to increase afterload.31
In the current era of new pharmacologic agents
for the treatment of heart failure, such as
Entresto (sacubitril/valsartan), which is a powerful vasodilator,32 consideration should be given
to suspending these medications, before the
intervention and until other contributing factors,
such as dehydration or tachycardia, have
resolved.
In the setting of hemodynamic compromise
there have been several reports of urgent percutaneous alcohol septal ablation performed to
reduce LVOT obstruction.16,33 Alcohol septal
ablation is a transcatheter therapy used for the
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treatment of LVOT obstruction in patients with
hypertrophic cardiomyopathy.34 Alcohol is
selectively injected into septal branches of the
left anterior descending artery that perfuse the
obstructive segment of the interventricular
septum, resulting in a confined myocardial
infarction. This results in a reduction of the
LVOT gradient that shows comparable efficacy
to that of surgical septal myectomy in terms
of mortality, functional status, ventricular
arrhythmia, reinterventions, and postprocedure
mitral regurgitation.35 Complications of alcohol
septal ablation include, however, permanent
atrioventricular block in approximately 10% of
patients.35 Successful use of alcohol septal ablation was previously described to treat LVOT
obstruction following mitral valve annuloplasty.16 Later, individual case reports have
demonstrated the hemodynamic benefits of
alcohol septal ablation for the treatment of
acute LVOT obstruction following transcatheter
mitral valve-in-MAC procedures.33,36 Likewise,
a recent small series of patients treated with
alcohol septal ablation following valve-in-MAC
also demonstrated acute postprocedural
amelioration in LVOT gradients (Fig. 2).37 Early
results of incorporation of preemptive alcohol
septal ablation before TMVR in patients stratified as high risk for LVOT obstruction postprocedure have shown this technique to be feasible in
the hands of centers with experience with
alcohol septal ablation and treatment of hypertrophic cardiomyopathy. Alcohol septal ablation
is a relatively simple procedure, although it has

been associated with different degrees of
atrioventricular block, need for permanent pacemaker implantation, and malignant arrhythmias.34 Therefore, thoughtful consideration
should be given before recommending this therapy routinely for patients with TMVR.
Alternative approaches to the management
of LVOT obstruction focus on primary prevention before prosthesis implantation to circumvent later hemodynamic compromise. Two
different methods have been proposed for prevention of LVOT obstruction. The first involves
laceration of the AML before mitral valve implantation38 and the other aims to preserve LVOT
patency by concomitant balloon inflation during
transcatheter heart valve deployment.
SAM has been identified as a causative factor
in both fixed and dynamic LVOT obstruction. As
described by Greenbaum and colleagues, an
elongated AML may interfere directly with the
functioning of an implanted transcatheter valve
in the mitral position by prolapsing through the
valve or may affect closure of the leaflets of
the bioprosthetic valve. Additional factors such
as volume depletion may worsen a dynamic
obstruction provoked by the AML protrusion
into the LVOT. A new percutaneous approach
has been studied in animals to establish proof
of concept and involves the intentional laceration of the A2 segment of the mitral valve using
a coronary wire and radiofrequency ablation.39
This technique, named LAMPOON, or laceration
of the AML to prevent LVOT obstruction procedure, requires retrograde access to the left
Fig. 2. CT analysis of neo-LVOT
pre- and postalcohol septal
ablation.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on May 13, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Fundamentals of LVOTO

atrium via the aortic valve and placement of 2
coronary guiding catheters, one in the LVOT
adjacent to the aortomitral curtain and the other
in the left atrium. A coronary guidewire is then
advanced through an insulated polymer jacket
via the LVOT catheter and electrified to perforate the anterior mitral leaflet and is then snared
by the catheter to form a loop in the left atrium.
This loop is then energized and withdrawn,
lacerating the A2 segment of the AML. The procedure successfully lacerated the anterior leaflet
in the animals studied without evidence of
chordal disruption.39
The LAMPOON procedure has been also
tested to prevent LVOT obstruction in 5 patients
with mitral valve disease and prohibitive surgical
risk before transcatheter mitral valve intervention.38 Preprocedural imaging is crucial in planning for LAMPOON. To ensure higher
likelihood of success in perforating the leaflet
scallop of entrance followed by tear, the anterior
mitral leaflet must not be overly calcified. However, despite LAMPOON, Khan and colleagues40 have demonstrated that there is no
true curative prevention for LVOT obstruction
in transcatheter valve implantation. The
LAMPOON procedure is able to be performed
at the time of TMVR but will only be able to increase the predicted neo-LVOT to the level of
the skirt of the transcatheter heart valve being
implanted. If the predicted skirt neo-LVOT is
less than 150 mm2, there still exists a profound
risk of iatrogenic LVOT obstruction. The
LAMPOON procedure will be studied further in
an early feasibility study funded by the NHLBI
(Intentional Laceration of the Anterior Mitral
Leaflet to Prevent Left Ventricular Outflow
Tract Obstruction During Transcatheter Mitral
Valve Implantation, ClinicalTrials.gov Identifier,
NCT03015194). A total of 60 patients will be
enrolled. Key inclusion criteria include severe
symptomatic native mitral valve failure after
mitral annuloplasty repair or related to MAC,
extremely high or prohibitive risk for surgical
mitral valve replacement and indication for
TMVR, high or prohibitive risk of LVOT obstruction (predicted neo-LVOT <200 mm2), or transcatheter heart valve dysfunction due to long/
redundant AML, as determined by the multidisciplinary institutional heart team. The primary
outcome is technical success at 30 days.
Herrmann and colleagues41 have recently
described the use of a perfusion balloon placed
in the LVOT to prevent LVOT obstruction in a
case report. The perfusion balloon was
advanced retrogradely into the LVOT and
inflated under rapid pacing before transcatheter

heart valve deployment in the mitral position.
The perfusion balloon maintained the patency
of the LVOT and permitted outflow while positioning and deploying the prosthetic device. In
addition, simultaneous inflation with the mitral
valve prosthesis prevented protrusion and overflaring of the mitral prosthesis toward the LVOT.
According to the investigators, no significant
LVOT obstruction was observed postintervention in this case.41 This approach has been
used in similar cases with a standard valvuloplasty balloon, using a kissing balloon inflation
to maintain LVOT patency, identify the landing
zone, and orient the transcatheter valve.42 The
long-term implications of such a technique are
as yet unknown and require further experience.

LONG-TERM IMPLICATIONS OF LEFT
VENTRICULAR OUTFLOW TRACT
OBSTRUCTION POST-TRANSCATHETER
MITRAL VALVE REPLACEMENT
The long-term outcomes of patients with LVOT
obstruction post-TMVR still remain to be clarified. Data gathered from surgical valve repair/
replacement complicated by LVOT obstruction
have roughly identified 2 main groups of patient:
those who can be managed with medical therapy, namely beta-blockade and prevention of
hypovolemia, and those requiring further mechanical intervention to resolve obstruction.43,44
Early experience from transcatheter mitral valve
therapies, although scarce, have also showed
success with medical therapy,45 but requirement
for repeat interventions in some cases.46 One of
the earliest case series of surgical patients with
LVOT obstruction postmitral annuloplasty
observed 12 patients postmitral valve repair.47
In 5 patients, surgical reintervention was
required immediately postrepair. In the remaining 7 patients, no further intervention was necessary at 27 months, and there was no evidence of
secondary left ventricular hypertrophy on followup despite persistent LVOT obstruction. The
largest published surgical case series followed
the outcomes of 174 patients postmitral valve
repair with persistent SAM.31 In this cohort of
patients treated between 1993 and 2002 at the
Mayo Clinic, 174 out of 2076 mitral repair patients had evidence of SAM intraoperatively. Of
these patients, 20% (n 5 34) also had evidence
of LVOT obstruction. In most of the cases,
SAM resolved before hospital discharge; however, one patient with LVOT obstruction did
require surgical removal of the annuloplasty
band. Late follow-up (median 4.7 years) was
available in 139 patients, amongst whom 4 had
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LVOT obstruction, yet no further intervention
was required at follow-up.
Insights regarding the long-term impact of
LVOT obstruction may be deduced also from
the clinical experience with hypertrophic cardiomyopathy, notwithstanding the noticeable disparities between these 2 entities. The 2014
European Society of Cardiology Guidelines for
Hypertrophic Cardiomyopathy reiterate the definition of LVOT obstruction as a gradient greater
than or equal to 30 mm Hg, while setting the
threshold for intervention at greater than or
equal to 50 mm Hg.48 These guidelines endorse
general measures such as avoidance of dehydration and medical therapy that may worsen LVOT
obstruction. The mainstay of medical therapy is
nonvasodilating
beta-blockers.
Noticeably,
there are no data to support treatment of
LVOT obstruction in asymptomatic patients.
Early studies of patients with hypertrophic cardiomyopathy had identified LVOT obstruction
as a risk factor for sudden death in this population at a threshold of 30 mm Hg, yet the likelihood of death did not increase further in those
with LVOT gradients above 30 mm Hg.49 Further
work, however, has suggested an increased mortality risk associated with increased LVOT
gradient; however, in asymptomatic patients,
all-cause mortality was low despite LVOT
obstruction, implying that intervention may be
unwarranted in the absence of symptoms.50
LVOT obstruction is a recognized risk factor for
sudden death in patients with hypertrophic cardiomyopathy and must be part of risk stratification in these patients.51 Of note, it is still
uncertain whether interventions to decrease
LVOT obstruction ameliorate the risks of sudden
death in patients with hypertrophic cardiomyopathy. For patients without hypertrophic cardiomyopathy but iatrogenic LVOT obstruction, the
risks are even less clear and remain to be
elucidated.

SUMMARY
LVOT obstruction is a well-known phenomenon
that may occur after surgical mitral valve repair or
replacement. Advancements in patient identification and surgical techniques have successfully
addressed this issue in most cases. The risk of
LVOT obstruction is a major limitation to the
wide adoption of TMVR. The risk of TMVR is greatest in the setting of valve-in-MAC, then valve-inring, and least (although not zero) with valve-invalve. Preprocedural imaging, generally by CT,
should focus on modeling the potential neoLVOT area. Potential mechanical intervention to

prevent LVOT obstruction in high-risk cases includes intentional laceration of the anterior mitral
leaflet (the LAMPOON procedure) or alcohol
septal ablation. Kissing balloon inflation or the
use of a perfusion balloon has also been proposed.
If LVOT obstruction does occur postprocedure,
appropriate medical management includes betablockade, hydration, and volume resuscitation.
Alcohol septal ablation in the setting of TMVRinduced LVOT obstruction may be therapeutic.
However, the threshold at which intervention
should be performed in the asymptomatic patient
is unknown. Novel transcatheter heart valves technologies that proactively address the anterior
mitral leaflet may be advantageous.
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